Organic Active Ingredients TRIZ Cases

Pre-administering NSAIDs before lipid nanoparticle infusion reduces inflammatory mediator concentration and prevents hypertension.

A two-step chemical induction system using rimiducid and rapamycin to trigger apoptosis in therapeutic cells expressing inducible caspase polypeptides.

A CCR2-targeting copper nanocluster delivers chemotherapeutic agents to pancreatic cancer cells.

Isotopic substitution stabilizes transthyretin, preventing amyloid fibril deposition in organs.

Sustained-release glucose pellets eliminate frequent dosing and digestive intolerance from raw corn starch therapy, ensuring stable blood glucose levels.

Recombinant constructs reduce HLA-I expression to protect transplanted cells from immune rejection, eliminating the need for complex donor matching.

Pyridine carbamate compounds target GluN2B receptors, addressing the lack of specific modulators for neurological disorders.

Hydrophobic pockets in PEGylated telodendrimers isolate Amphotericin B monomers, reducing nephrotoxicity while maintaining antifungal efficacy.

Codon optimization of the spike protein gene resolves low expression efficiency in human cells while maintaining safe, simplified manufacturing.

Fusing six immunogenic fragments into a single polypeptide overcomes weak immune responses from individual recombinant proteins while maintaining safety.

Tannin-chitosan composite films dissolve rapidly to release active pharmaceutical ingredients.

dsRNA agents inhibit HMGB1 expression to reduce liver inflammation and fibrosis in non-alcoholic fatty liver disease.

Pyrrolidine compounds inhibit alpha v beta 6 integrin to block TGFbeta activation.

Ester and carbamate prodrug derivatives enhance oral bioavailability of protease inhibitors, resolving rapid metabolism issues that limit antiviral efficacy.

Intravenous decidua stromal cells reduce cytokine storms and improve oxygen saturation in acute respiratory distress syndrome.

Lipid nanoparticles deliver mRNA encoding botulinum toxin to reduce antibody formation risks while enabling localized protein expression.

A nicotine pouch filler with release control excipients and a multi-fiber packaging material modulate nicotine diffusion into saliva.

Low molecular weight marine algal glycoproteins stimulate endogenous insulin secretion to maintain stable glucose levels after treatment withdrawal.

Polyoxysorbitan esters and a base accelerate ibuprofen solubilization, overcoming slow release rates of conventional formulations.

Oral small molecule inhibitors replace monoclonal antibodies to lower plasma LDL cholesterol via targeted PCSK9 reduction.

Suppressing POLQ reduces alternative non-homologous end joining interference, improving Cas9-mediated DNA editing precision.

Systematic variation of R1 and R2 substituents on the irciniastatin core improves anticancer selectivity while managing synthesis complexity.

Specific heterocyclic compounds inhibit IDO1 enzyme activity, addressing insufficient efficacy of current therapeutic agents in treating cancers.

RALA peptide mediates intracellular mRNA delivery to prime CD8+ T cells, treating existing HPV infections.

N-alkyl-N-heteroarylsulfonamide compounds disrupt the HIF-1 transcriptional complex to overcome tumor resistance and pleiotropic effects.

Cationic liposomes stabilize RNA via electrostatic binding, reducing viral vector toxicity while maintaining high encapsulation efficiency.

Bangia fusco-purpure and Lactobacillus fermentation produces a supernatant with high alpha-glucosidase inhibition rates.

Standardized licorice extract with specific glycyrrhizin to liquiritin ratios addresses the lack of active component confirmation in herbal liver treatments.

Yukmijihwang-tang extract reduces metformin-induced liver and kidney damage while improving bioavailability.

Biodegradable ionizable lipids form delivery vehicles that penetrate cell membranes, resolving suboptimal transfection efficiency in hard-to-transfect cells.

Cyclic glycine-proline biomarker tracks active insulin-like growth factor 1 levels using blackcurrant anthocyanin extracts.

A Bacillus coagulans MTCC 5856 and anthocyanin composition restores normal mucosal architecture in the gastrointestinal tract.

Segmented amphipathic peptide nanoparticles convert cold tumors into hot tumors by inducing immunogenic cell death via visible light activation.

Hydroxyalkylated starch targets neoplasm-associated macrophages to reduce tumor growth while avoiding the toxic side effects of conventional chemotherapy.

Segmenting BET inhibitors into specific tricyclic structures resolves the trade-off between therapeutic effectiveness and limited treatment options.

Oxazolidinone derivatives inhibit HCV NS5A protein, reducing side effects and improving treatment efficacy for difficult patient groups.

Targeting nuclear PC4 prevents cancer recurrence by blocking DNA repair while reducing toxicity to normal cells.

A preservative-free l-epinephrine pharmaceutical formulation uses controlled pH and inert atmosphere packaging to maintain potency.

Anti-PMEL17 antibodies resolve specificity and efficacy trade-offs by targeting PMEL17-positive cancer cells with high affinity.

Chelating agents remove heavy metal ions while ethanol precipitation separates fucoidan from bacterial contaminants, improving extract purity.

Bioadhesive nanoparticles form covalent bonds with tumor cells to address systemic toxicity and limited efficacy of topical chemotherapies.

Volatile siloxane vehicle delivers vitamin E acetate to reduce crust resolution time from 15-20 days to 7-10 days.

Positively-charged cationic liposomes enhance cellular uptake of immune modulators to stimulate anti-tumor immunity.

Natural polyphenolic compounds cinnamtannin B1 and D1 decrease CD274 gene expression, replacing complex antibody therapies with oral administration.

Pyrrolidine compounds antagonize orexin receptors, addressing the lack of effective treatments for sleep disorders and insomnia.

Polycarbonate-ester polymers protect kojic acid from thermal degradation while enabling controlled hydrolytic release for stable personal care applications.

Solvent-based crystallization yields a non-hygroscopic crystal form that resolves polymorphic variability and improves drug stability.

Flagella beating drives algae-based microrobots through biological barriers, evading macrophage phagocytosis to treat pulmonary infections.

Vaccinium bracteatum leaf extract reduces immobility time and stress hormone levels, addressing the lack of safe natural resources for depression treatment.

Disulfide-linked peptide dimers resist proteolytic degradation to extend circulating plasma half-life for targeted drug delivery.

Targeting miR-134 expression overcomes drug-resistant epilepsy by altering synaptic plasticity mechanisms.

Formula I compounds modulate Kv3 channels via heterocyclic scaffolds to balance efficacy and safety.

A synergistic composition combining Galeopsis extract with spermidine and biotin induces autophagy in hair follicle cells.

Enzymatic conversion of cytotoxic cannabinoids to water-soluble glycosides in yeast cultures eliminates cellular toxicity and enables scalable isolation.

Hematopoietic prostaglandin D synthase inhibition blocks inflammatory pathways to treat sarcopenia without off-target side effects.

Sequential condensation, cyclization, and hydrolysis in a single vessel raise yield from 26% to 75% while lowering reaction temperatures.

Novel histamine H3 receptor ligands address research complexity by enabling versatile treatment of multiple neurological conditions.

Micronized Indibulin and hydrophilic surfactants resolve poor solubility, achieving bioavailability without lactic acid toxicity.

Co-crosslinked chitosan and polysaccharide matrix with zinc cations maintains viscosity after autoclave sterilization.

ZDHHC9 inhibition reduces RAS palmitoylation, bypassing direct targeting difficulties and limiting chemotherapy side effects.

Formula I compounds inhibit MDM2-p53 interaction via selective binding to the MDM2 pocket, avoiding P450 enzymes to reduce neurological side effects.

Electrophilic warhead compounds inhibit mutant K-Ras G12C activity, resolving ineffective treatment for proliferative diseases.

Peptidomimetic compounds target the FGF14:Nav1.6 complex to reduce side effects from broad-spectrum psychiatric treatments.

MuSK agonist antibodies activate receptors to maintain synaptic integrity, delaying denervation and improving motor function in ALS models.

Segmented benzothiadiazepine structures optimize NTCP binding affinity to block viral entry, reducing resistance risks inherent in existing therapies.

An LSD1 inhibitor targets transcriptional dysregulation in induced pluripotent stem cell models to treat Autism Spectrum Disorder.

15-Lipoxygenase enzyme recruits regulatory T cells into lymphedematous tissue, resolving chronic inflammation and restoring lymphatic function.

Chiral piperidine structures achieve selective class I inhibition, reducing off-target effects against class II enzymes.

Pyrimidine compounds form covalent bonds with target proteins, ensuring irreversible inhibition of kinase activity.

An enzyme catalyzes hydroxy derivatives from polyunsaturated fatty acids to enhance collagen synthesis and skin barrier strength.

A 3D rod array creates turbulence to deaggregate cohesive particles, resolving low lung deposition and high extrathoracic waste.

A nose-to-brain nimodipine formulation uses absorption enhancers to deliver drug directly to brain tissue.

Micronized brexpiprazole under 40 µm combined with specific binders resolves solubility and content uniformity challenges in tablet manufacturing.

Lipid-conjugated antisense oligonucleotides overcome poor bacterial uptake and enzymatic degradation to reverse antibiotic resistance.

Steroid-mimetic compounds down-regulate androgen receptors to overcome castration resistance in prostate cancer treatment.

Citric acid replaces toxic agents in cellulose hydrogels, eliminating harmful by-products while maintaining structural integrity and absorption.

Compound A selectively activates CB2 receptors to alleviate visceral pain without opioid side effects.

Formula VIIIa and VIIIb compounds treat brain cancers by crossing the blood-brain barrier while maintaining tubulin inhibition activity.

Modulating CCR3 via eotaxin-1 interaction mitigates synapse loss and reverses cognitive decline associated with aging.

Replacing halogenated solvents with a carbocation scavenger during deprotection raises yields above 85% while eliminating toxic waste.

Pharmacological combination replaces mechanical therapy, improving adherence while treating obesity hypoventilation syndrome.

A pharmaceutical adjuvant composition facilitates polypeptide drug release and absorption in the small intestine.

A synthetic human milk oligosaccharide composition increases relative abundance of Bifidobacterium adolescentis in the gut.

Adeno-associated virus delivers hPGIS gene to synthesize prostaglandin I2, inducing VEGF production and collateral vessel formation in ischemic tissues.

A combination therapy depletes circulating serum amyloid P component using a small molecule and targets deposits with an antibody.

Conjugated antisense oligomers enhance cellular uptake and binding affinity to treat Duchenne muscular dystrophy.

Pharmacologic inhibition of the CHFR-PARP1 interaction overcomes primary taxane resistance in chemotherapy.

Low-substituted hydroxypropyl cellulose and controlled D-mannitol maintain tablet hardness during humid storage while ensuring rapid disintegration.

A chemo-selective reduction reaction transforms a benzoate ester to a primary alcohol while maintaining a lactone at the aldehyde stage.

Crystalline rosuvastatin zinc salt forms via isopropyl alcohol suspension, resolving amorphous instability.

2-Pyridyloxy-3-ester-4-nitrile compounds antagonize orexin receptors to treat sleep disorders and insomnia.

A composition of Haematococcus pluvialis, Lycium ruthenicum, Cordyceps militaris, and nicotinamide enhances SOD enzyme activity.

Beta-alanine increases both slow and fast muscle fiber types while maintaining excellent safety profiles.

Recombinant agarase rGaa16B produces oligosaccharides that inhibit hyaluronidase, preventing hyaluronic acid degradation and skin aging.

Segmented amphiphilic triblock polymer forms micelles that encapsulate poorly soluble drugs while maintaining water solubility for easy removal.

Substituted amine compounds inhibit leukotriene A4 hydrolase activity to reduce leukotriene B4 production in inflammatory disorders.

Beta-ecdysterone lowers uric acid without hepatotoxicity or adverse reactions common in synthetic drugs.

Combining pentosan polysulphate with a PPARγ agonist increases mitochondrial activity while mitigating toxic side effects through synergistic dosing.